Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403

Immunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression-free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of adding post-transplant bortezomib consolidation (BC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Hematol
Autors principals: Kaplan, Lawrence D., Maurer, Matthew J., Stock, Wendy, Bartlett, Nancy L., Fulton, Noreen, Pettinger, Adam, Byrd, John C., Blum, Kristie A., LaCasce, Ann S., Hsi, Eric D., Liu, Yi Tian, Scott, David W., Hurd, David, Ruppert, Amy S., Hernandez-Ilizaliturri, Francisco, Leonard, John P., Cheson, Bruce. D.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486983/
https://ncbi.nlm.nih.gov/pubmed/32170769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25783
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars